Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.83 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CSK | P41240 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297030 | 0.94 | AURKA (0.88) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4289024 | 0.92 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4293803 | 0.92 | AURKA (0.88) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4286511 | 0.92 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL3488241 | 0.91 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4293621 | 0.91 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4286859 | 0.90 | AURKA (0.88) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4286728 | 0.90 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R | |
| SCHEMBL4297376 | 0.89 | AURKA (0.89) | AURKAAURKB | |
| SCHEMBL4290704 | 0.89 | AURKA (1.00) | AURKAAURKBEGFRKDRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | claimed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885EGFR 1016/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885EGFR 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.